Format:
Diagramme
ISSN:
1460-2105
Content:
Insulin-like growth factor type 1 receptor (IGF-1R) mediates resistance to epidermal growth factor receptor (EGFR) inhibition and may represent a therapeutic target. We conducted a multicenter, randomized, double blind, phase II/III trial of dalotuzumab, an anti-IGF-1R monoclonal antibody, with standard therapy in chemo-refractory, KRAS wild-type metastatic colorectal cancer.
In:
National Cancer Institute, Journal of the National Cancer Institute, Oxford : Oxford Univ. Press, 1941, 107(2015), 12, Seite 258, 1460-2105
In:
volume:107
In:
year:2015
In:
number:12
In:
pages:258
Language:
English
Author information:
Schmoll, Hans-Joachim
Bookmarklink
